Due Hanne, Svendsen Pernille, Bødker Julie Støve, Schmitz Alexander, Bøgsted Martin, Johnsen Hans Erik, El-Galaly Tarec Christoffer, Roug Anne Stidsholt, Dybkær Karen
Department of Haematology, Aalborg University Hospital, Hobrovej 18-22, 9100 Aalborg, Denmark; Department of Haematology, Aarhus University Hospital, Tage-Hansens Gade 2, 8000 Aarhus C, Denmark.
Department of Haematology, Aalborg University Hospital, Hobrovej 18-22, 9100 Aalborg, Denmark.
Biomed Res Int. 2016;2016:9513037. doi: 10.1155/2016/9513037. Epub 2016 May 16.
MicroRNAs have the potential to be useful biomarkers in the development of individualized treatment since they are easy to detect, are relatively stable during sample handling, and are important determinants of cellular processes controlling pathogenesis, progression, and response to treatment of several types of cancers including B-cell malignancies. miR-155 is an oncomiR with a crucial role in tumor initiation and development of several B-cell malignancies. The present review elucidates the potential of miR-155 as a diagnostic, prognostic, or predictive biomarker in B-cell malignancies using a systematic search strategy to identify relevant literature. miR-155 was upregulated in several malignancies compared to nonmalignant controls and overexpression of miR-155 was further associated with poor prognosis. Elevated expression of miR-155 shows potential as a diagnostic and prognostic biomarker in diffuse large B-cell lymphoma and chronic lymphocytic leukemia. Additionally, in vitro and in vivo studies suggest miR-155 as an efficient therapeutic target, supporting its oncogenic function. The use of inhibiting anti-miR structures indicates promising potential as novel anticancer therapeutics. Reports from 53 studies prove that miR-155 has the potential to be a molecular tool in personalized medicine.
微小RNA有潜力成为个性化治疗发展中有用的生物标志物，因为它们易于检测，在样本处理过程中相对稳定，并且是控制包括B细胞恶性肿瘤在内的几种癌症的发病机制、进展和对治疗反应的细胞过程的重要决定因素。miR-155是一种癌基因miRNA，在几种B细胞恶性肿瘤的肿瘤起始和发展中起关键作用。本综述使用系统检索策略来识别相关文献，阐明了miR-155作为B细胞恶性肿瘤的诊断、预后或预测生物标志物的潜力。与非恶性对照相比，miR-155在几种恶性肿瘤中上调，并且miR-155的过表达进一步与不良预后相关。miR-155的表达升高在弥漫性大B细胞淋巴瘤和慢性淋巴细胞白血病中显示出作为诊断和预后生物标志物的潜力。此外，体外和体内研究表明miR-155是一个有效的治疗靶点，支持其致癌功能。使用抑制性抗miR结构显示出作为新型抗癌疗法的有前景的潜力。来自53项研究的报告证明，miR-155有潜力成为个性化医学中的分子工具。
